Highlights

  • 4DMedical has launched CLEAR (Contrast-free Lung Evaluation for Acute Risk), a multi-centre clinical evidence program anchored at Massachusetts General Hospital, to fast-track CT:VQ entry into the acute pulmonary embolism imaging market.
  • The program targets the approximately 5 million CTPA scans performed annually in the U.S. for suspected PE, expanding 4DMedical's obtainable market from approximately $0.5 billion to US$3 billion.
  • 4DMedical has committed approximately US$2 million in funding for CLEAR, with MGH as the principal enrolling site in a prospective head-to-head comparison of CT:VQ against CTPA for patients with suspected PE.

 

4DMedical Limited (ASX:4DX) has delivered a 1,137.50% return over the twelve months to 2 June 2026, making it one of the most significant performers in the ASX healthcare technology sector over that period. The stock was trading at A$3.95 on the announcement date, down 3.42% intraday — a modest pullback on a day when the company launched what management characterises as a program that could multiply its addressable market sixfold. The negative intraday price movement may reflect profit-taking after a period of exceptional gains, or uncertainty around the timeline to commercialisation from a clinical study that will take time to generate data.

The company's commercial traction in its core market — displacing nuclear ventilation-perfusion (VQ) scans with its CT:VQ technology — has been the primary driver of the extraordinary price appreciation. The CLEAR program is an attempt to Leverage that established beachhead into a fundamentally larger adjacent market opportunity.

The Pulmonary Embolism Imaging Problem

Pulmonary embolism is a major acute cardiovascular condition. Epidemiological data indicate approximately 600,000–650,000 diagnosed clinical episodes per annum in the United States, with the true burden likely higher due to under-diagnosis. PE presents with non-specific symptoms — chest pain and shortness of breath — that overlap with many other conditions, and the consequences of a missed diagnosis include significant morbidity and, in a meaningful proportion of cases, sudden death.

The diagnostic pathway response to this clinical uncertainty has been to default toward high-sensitivity imaging. CT Pulmonary Angiography has become the near-universal imaging modality for suspected PE since around 2004, with utilisation reportedly growing fourfold at multiple large health systems. However, this Volume growth has been accompanied by declining diagnostic Yield: across large cohorts, the positive yield of CTPA for confirmed PE has been reported in the range of 3–10%, meaning the vast majority of patients scanned — 90–97% — are exposed to iodinated contrast agents and associated imaging costs without a PE being confirmed. The aggregate U.S. CTPA volume for suspected PE is widely estimated at approximately 4–6.5 million studies annually, with 5 million as a conservative midpoint.

This dynamic — high imaging volumes, low diagnostic yield, contrast exposure risk, and persistent costs — represents the clinical problem that 4DMedical is positioning CT:VQ to address.

CT:VQ Technology and Its FDA-Cleared Foundation

4DMedical's CT:VQ solution generates quantitative, three-dimensional ventilation and perfusion maps from routine, non-contrast inspiratory and expiratory CT scans. The ventilation-perfusion principle — using the ventilation-perfusion mismatch pattern to identify areas of lung not receiving blood flow — is well established in nuclear medicine VQ scanning, which has been a validated diagnostic approach for PE for decades. CT:VQ applies this established physiological principle within a standard CT workflow, eliminating the need for nuclear tracers, iodinated contrast, or specialised nuclear medicine infrastructure.

Critically, the underlying VQ indication for CT:VQ is already FDA-cleared, which meaningfully de-risks the regulatory pathway for the PE application. 4DMedical is not seeking a new indication from scratch — it is seeking clinical evidence to support the application of an already-approved technology in an adjacent, higher-volume clinical scenario. This regulatory positioning distinguishes the CLEAR program from a standard new device approval process.

The CLEAR Program: Design and Partner Selection

CLEAR is a multi-centre, multinational, prospective, observational study comparing CT:VQ directly against CTPA in patients presenting with suspected acute PE. The study is anchored at Massachusetts General Hospital, the original and largest teaching hospital of Harvard Medical School, through a clinical research agreement with Mass General Brigham, the integrated academic healthcare system that encompasses MGH and its affiliated teaching hospitals.

The significance of MGH as the lead site cannot be overstated in the context of clinical evidence generation. Studies originating from major academic medical centres affiliated with institutions of Harvard's standing carry weight with regulatory bodies, hospital procurement committees, and the physician community. The ability to reference MGH data in commercial conversations and publications represents a credibility asset that 4DMedical can leverage across its broader market development activities.

Total committed funding for CLEAR is approximately US$2 million, covering patient recruitment, imaging analysis, and data generation. Relative to the market opportunity being targeted — a US$2.5–3 billion annual imaging segment — this is a Capital-efficient approach to generating the clinical validation evidence required for broad adoption.

Market Size and Strategic Positioning

4DMedical's current core market, nuclear VQ scanning, is approximately 1 million scans per annum in the United States. The company has been displacing this market, with CT:VQ capturing share at what management describes as an accelerating pace. The nuclear VQ market alone implies an obtainable Revenue opportunity of roughly $0.5 billion at current scanner Economics.

The CTPA-dominated PE market — approximately 5 million scans annually at estimated per-scan economics — represents a US$2.5 billion incremental opportunity, bringing the total CT:VQ obtainable market to US$3 billion if CLEAR generates data supporting adoption in acute PE workflows. The company is simultaneously pursuing a separate European market entry that management characterises as adding approximately 50% to the existing market opportunity. The combined effect of the European expansion and the PE market entry, if both are realised, would imply a market opportunity substantially larger than the current nuclear VQ replacement trajectory alone can support.

The 2026 Acquisition of contextflow, referenced in 4DMedical's company description, adds AI capabilities to the product portfolio — a component of the company's broader strategy of integrating advanced image analysis with its functional lung assessment technology.

Conclusion

4DMedical's CLEAR program represents a deliberate and capital-efficient attempt to expand CT:VQ from a nuclear VQ replacement product into a potential standard-of-care alternative in one of the highest-volume acute imaging workflows in U.S. emergency medicine. The Partnership with Mass General Brigham and the head-to-head design against CTPA are structured to generate the quality of clinical evidence required to support reimbursement coverage, hospital formulary adoption, and physician behaviour change. With US$2 million committed and an existing FDA-cleared technology as the foundation, the Risk-adjusted Investment in CLEAR is modest relative to the magnitude of the opportunity it is designed to unlock. The timeline to commercial impact from a prospective clinical study is measured in years rather than quarters, meaning CLEAR's contribution to revenues will be a future-period story — but the strategic logic of pursuing it now, while the core VQ market is growing, is clearly evident.